A pilot study of antidepressant-induced mania in pediatric bipolar disorder: Characteristics, risk factors, and the serotonin transporter gene

被引:64
作者
Baumer, Fiona M. [1 ]
Howe, Meghan [1 ]
Gallelli, Kim [1 ]
Simeonova, Diana Lorgova [1 ]
Hallmayer, Joachim [1 ]
Chang, Kiki D. [1 ]
机构
[1] Stanford Univ, Sch Med, Div Child & Adolescent Psychiat, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA
关键词
bipolar disorder; child; adolescent; antidepressant-induced mania; suicide; serotonin transporter gene;
D O I
10.1016/j.biopsych.2006.06.010
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Antidepressant-induced mania (ALV) has been described in bipolar disorder (BD) and has been associated with the sbort-allele of the serotonin transporter gene (5-HTT). We wished to investigate the frequency of and risk factors for AIM in pediatric patients with or at high risk for BD. Methods: Fifty-two children and adolescents (30 with BD and 22 with subthreshold manic symptoms, 15.1 +/- 3.4 years old), all with a parent with BD, were interviewed with their parents for manic/depressive symptoms occurring before and after past antidepressant treatment. The 47 subjects with serotonin reuptake inhibitor (SSRI) exposure were genotyped for the 5-HTT polymorphism. Results: Fifty percent of subjects were AIM+ and 25.5% had new onset of suicidal ideation. The AIM+ and AIM- groups did not differ significantly in relation to allele (p =.36) orgenotype (p =.53) frequencies of the 5-HTT polymorphism. The AIM+ subjects were more likely to have more comorbidities (3.2 vs. 2.4; p =.02) and be BD type 1 (p =.04) than AIM- subjects. Conclusions: Youth with or at high risk for BD may be particularly vulnerable to SSRI AIM and thus should be monitored if given SSRIs. In this preliminary study, we did not find that the 5-HTT polymorphism significantly influenced vulnerability to AIM.
引用
收藏
页码:1005 / 1012
页数:8
相关论文
共 44 条
[1]  
ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229
[3]   Medication use in children and adolescents treated in the community for bipolar disorder [J].
Bhangoo, RK ;
Lowe, CH ;
Myers, FS ;
Treland, J ;
Curran, J ;
Towbin, KE ;
Leibenluft, E .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (04) :515-522
[4]   Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young [J].
Biederman, J ;
Mick, E ;
Spencer, TJ ;
Wilens, TE ;
Faraone, SV .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2000, 10 (03) :185-192
[5]   The rewards of reducing risk [J].
Brent, DA .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2004, 158 (08) :824-825
[6]   Drug-induced disinhibition in psychiatrically hospitalized children [J].
Carlson, GA ;
Mick, E .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (02) :153-163
[7]   Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: Report of a consensus conference [J].
Carlson, GA ;
Jensen, PS ;
Findling, RL ;
Meyer, RE ;
Calabrese, J ;
DelBello, MP ;
Emslie, G ;
Flynn, L ;
Goodwin, F ;
Hellander, M ;
Kowatch, R ;
Kusumakar, V ;
Laughren, T ;
Leibenluft, E ;
McCracken, J ;
Nottelmann, E ;
Pine, D ;
Sachs, G ;
Shaffer, D ;
Simar, R ;
Strober, M ;
Weller, EB ;
Wozniak, J ;
Youngstrom, EA .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (01) :13-27
[8]   An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression [J].
Chang, K ;
Saxena, K ;
Howe, M .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (03) :298-304
[9]   Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms [J].
Chang, KD ;
Dienes, K ;
Blasey, C ;
Adleman, N ;
Ketter, T ;
Steiner, H .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (08) :936-942
[10]   Clinical implications of antidepressant and stimulant use on switching from depression to mania in children [J].
Craney, J ;
Geller, B .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (02) :201-204